Valeant's looming M&A hiatus deals blow to investment banks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cowen Raises Price Target on AT&T (T) After Updating Model to Reflect Company Changes
October 27, 2015 10:24 AM EDTCowen reiterated an Outperform rating on AT&T (NYSE: T), and raised the price target to $41.00 (from $40.00), after updating model to reflect the new way in which the company breaks out revenue.
Analyst Colby Synesael commented, "We are updating our... More
Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain Treatment
October 26, 2015 6:26 AM EDTEndo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is... More
UBS Reiterates Buy on AT&T (T) Following 3Q Earnings
October 23, 2015 10:19 AM EDTUBS reiterated a Buy rating and $42.00 price target on AT&T (NYSE: T), following the company's 3Q earnings results. AT&T reported 3Q EPS of $0.74, equating to 14% yoy growth. 4Q seasonality should not be as bad as in past years, suggesting... More
